Abstract |
In a phase II study, daclizumab was given as single second-line agent to 62 patients with steroid-refractory acute graft-versus-host disease (aGVHD). Complete resolution of aGVHD was achieved in 68.8% of patients. This response rate was significantly associated with a lower number of involved organs and smaller extent of skin involvement. The 4-year event-free survival (EFS) was 54.6%. Grade > or =III aGVHD, > or =2 involved organs at baseline and patient age >18 years were independently associated with lower EFS. Daclizumab could be a suitable alternative treatment for aGVHD, particularly when limited to the skin or gastrointestinal tract.
|
Authors | Pierre Bordigoni, Sophie Dimicoli, Laurence Clement, Cédric Baumann, Alexandra Salmon, Francis Witz, Pierre Feugier |
Journal | British journal of haematology
(Br J Haematol)
Vol. 135
Issue 3
Pg. 382-5
(Nov 2006)
ISSN: 0007-1048 [Print] England |
PMID | 16984386
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Immunoglobulin G
- Immunosuppressive Agents
- Daclizumab
|
Topics |
- Acute Disease
- Adolescent
- Adult
- Age Factors
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Child
- Child, Preschool
- Daclizumab
- Female
- Graft vs Host Disease
(drug therapy, mortality, pathology)
- Humans
- Immunoglobulin G
(adverse effects, therapeutic use)
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Infant
- Male
- Middle Aged
- Prospective Studies
- Remission Induction
- Stem Cell Transplantation
(adverse effects)
- Survival Analysis
- Treatment Outcome
|